Mustang Bio, Inc. (NASDAQ:MBIO) Short Interest Update

Mustang Bio, Inc. (NASDAQ:MBIO) saw a large drop in short interest during the month of September. As of September 30th, there was short interest totalling 382,100 shares, a drop of 41.8% from the September 15th total of 656,400 shares. Approximately 1.1% of the shares of the company are short sold. Based on an average daily trading volume, of 1,300,000 shares, the short-interest ratio is presently 0.3 days.

Mustang Bio Price Performance

NASDAQ:MBIO opened at $0.22 on Friday. The business’s 50 day moving average is $0.28 and its two-hundred day moving average is $0.37. Mustang Bio has a 52 week low of $0.13 and a 52 week high of $2.11.

Mustang Bio (NASDAQ:MBIO) last released its earnings results on Tuesday, August 13th. The company reported ($0.24) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.10). As a group, equities analysts expect that Mustang Bio will post -0.7 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Koss Olinger Consulting LLC acquired a new stake in shares of Mustang Bio during the 2nd quarter worth approximately $47,000. Thoroughbred Financial Services LLC acquired a new stake in shares of Mustang Bio during the 2nd quarter worth approximately $25,000. Finally, Virtu Financial LLC acquired a new stake in shares of Mustang Bio during the 1st quarter worth approximately $31,000. Institutional investors own 9.95% of the company’s stock.

About Mustang Bio

Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.